1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Infecciosas

Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Pérez-Molina JA, Martinez-Perez A, Serre N, Treviño B, Ruiz-Giardín JM, Torrús D, Goikoetxea J, Echevarría EM, Malmierca E, Rojo G, Calabuig E, Gutierrez B, Norman F, Lopez-Velez R.

    Characteristics of HIV infected individuals traveling abroad. Results from the plus REDIVI Collaborative Network

    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA . 34(2): 108-113. Nº de citas: 7

    [doi:10.1016/j.eimc.2015.03.023]

  • Martínez-Sellés M, Bouza E, Díez-Villanueva P, Valerio M, Fariñas MC, Muñoz-García AJ, Ruiz-Morales J, Gálvez-Acebal J, Antorrena I, de la Hera Galarza JM, Navas E, Muñoz P.

    Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation

    EUROINTERVENTION . 11(10): 1180-1187. Nº de citas: 36

    [doi:10.4244/EIJY15M02_05]

  • Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC, Terashima A, Samalvides F, Pérez-Molina JA, Plana MN.

    Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection

    COCHRANE DATABASE OF SYSTEMATIC REVIEWS . (1): . Nº de citas: 188

    [doi:10.1002/14651858.CD007745.pub3]

  • Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feíto M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P.

    Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial.

    AIDS . 30(1): 75-82. Nº de citas: 16

    [doi:10.1097/QAD.0000000000000886]

  • Monge-Maillo B, López-Vélez R.

    Treatment Options for Visceral Leishmaniasis and HIV Coinfection.

    AIDS REVIEWS . 18(1): 32-43. Nº de citas: 21

  • Casado JL, Bañón S, Santiuste C, Serna J, Guzman P, Tenorio M, Liaño F, Rey JM.

    Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir

    AIDS . 30(2): 231-239. Nº de citas: 29

    [doi:10.1097/QAD.0000000000000901]

  • Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Wook-Chun T, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

    Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

    PLOS PATHOGENS . 12(1): . Nº de citas: 38

    [doi:10.1371/journal.ppat.1005381]

  • Casado JL, Marín A, Romero V, Bañón S, Moreno A, Perez-Elías MJ, Moreno S, Rodriguez-Sagrado MA.

    The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens

    HIV MEDICINE . 17(1): 46-55. Nº de citas: 13

    [doi:10.1111/hiv.12280]

  • Casado JL, Mena A, Bañón S, Castro A, Quereda C, Moreno A, Pedreira J, Moreno S.

    Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis

    HIV MEDICINE . 17(1): 62-67. Nº de citas: 9

    [doi:10.1111/hiv.12274]

  • Corral I, Quereda C, Dronda F, Navas E, Hermida JM, Moreno C, Martínez-San-Millán J.

    Progressive multifocal leukoencephalopathy mimicking milliary CNS tuberculosis

    JOURNAL OF NEUROVIROLOGY . 21(6, SI): 691-693. Nº de citas: 1

    [doi:10.1007/s13365-015-0367-6]

  • Martínez-Bonet M, Isabel Clemente M, Jesús Serramía M, Muñoz E, Moreno S, Ángeles Muñoz-Fernández M.

    Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1

    SCIENTIFIC REPORTS . 5: 16445-16445. Nº de citas: 38

    [doi:10.1038/srep16445]

  • Casado JL, Bañón S.

    Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection

    EXPERT REVIEW OF CLINICAL PHARMACOLOGY . 8(6): 709-718. Nº de citas: 6

    [doi:10.1586/17512433.2015.1090873]

  • Santos JR, Blanco JL, Masiá M, Gutiérrez F, Pérez-Elías MJ, Iribarren JA, Force L, Antela A, Knobel H, Salavert M, López Bernaldo De Quirós JC, Pino M, Paredes R, Clotet B.

    Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 70(11): 3087-3095. Nº de citas: 11

    [doi:10.1093/jac/dkv205]

  • Rubio-Terrés C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Lletí M, Toledo A, Anguita P, Rubio-Rodríguez D, Watt M, Gani R.

    Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES . 34(11): 2213-2223. Nº de citas: 26

    [doi:10.1007/s10096-015-2472-0]

  • Parrondo J, Moreno S, Losa JE, Berenguer J, Martinez-Sesmero JM, Grasset E, Cenoz-Gomis S.

    Cost-Utility Analysis of Dolutegravir/Abacavir/Lamivudine (Dtg/Abc/3tc) as a Single Tablet Treatment of Naïve Hiv Infected Patientss.

    VALUE IN HEALTH . 18(7): . Nº de citas: 1

    [doi:10.1016/j.jval.2015.09.1507]

  • Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR, NEAT001/ANRS143 Study Group.

    Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

    LANCET HIV . 2(11): 464-473. Nº de citas: 69

    [doi:10.1016/S2352-3018(15)00181-2]

  • San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network, Spain.

    Effect of delaying prophylaxis against CMV in D plus /R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease

    JOURNAL OF INFECTION . 71(5): 561-570. Nº de citas: 14

    [doi:10.1016/j.jinf.2015.06.013]

  • Pérez-Molina JA, Perez AM, Norman FF, Monge-Maillo B, López-Vélez R.

    Old and new challenges in Chagas disease

    The Lancet. Infectious diseases . 15(11): 1347-1356. Nº de citas: 81

    [doi:10.1016/S1473-3099(15)00243-1]